Essential roles of toll-like receptors in atherosclerosis

Current Medicinal Chemistry

Volumn 23, Issue 5, 2016, Pages 431-454

  Lin, Juntang ^a,b   Kakkar, Vijay ^c   Lu, Xinjie ^a,c  

^a XINXIANG MEDICAL UNIVERSITY   (China)

^b FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^c THROMBOSIS RESEARCH INSTITUTE   (United Kingdom)

Author keywords

Atherosclerosis; Cardiovascular disease; Inflammation; Knock out mouse; Plaque; Toll like receptor

Indexed keywords

BETA INTERFERON; INTERLEUKIN 1 RECEPTOR; MATRIX METALLOPROTEINASE; MYELOID DIFFERENTIATION FACTOR 88; PATHOGEN ASSOCIATED MOLECULAR PATTERN; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 1; TOLL LIKE RECEPTOR 10; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 5; TOLL LIKE RECEPTOR 6; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8; TOLL LIKE RECEPTOR 9; TOLL LIKE RECEPTOR ADAPTOR MOLECULE 1; LIGAND;

ADAPTIVE IMMUNITY; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CELLULAR DISTRIBUTION; CONSENSUS SEQUENCE; CRYSTAL STRUCTURE; HUMAN; INNATE IMMUNITY; INTRACELLULAR SIGNALING; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN STRUCTURE; ANTAGONISTS AND INHIBITORS; CHEMISTRY; IMMUNOLOGY; MOLECULAR MODEL;

ATHEROSCLEROSIS; HUMANS; LIGANDS; MODELS, MOLECULAR; TOLL-LIKE RECEPTORS;

EID: 84960091403     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/0929867323666151207111408     Document Type: Article

References (266)

1. Lozano, R.; Naghavi, M.; Foreman, K.; Lim, S.; Shibuya, K.; Aboyans, V.; Abraham, J.; Adair, T.; Aggarwal, R.; Ahn, S.Y.; Alvarado, M.; Anderson, H.R.; Anderson, L.M.; Andrews, K.G.; Atkinson, C.; Baddour, L.M.; Barker-Collo, S.; Bartels, D.H.; Bell, M.L.; Benjamin, E.J.; Bennett, D.; Bhalla, K.; Bikbov, B.; Bin, A.A.; Birbeck, G.; Blyth, F.; Bolliger, I.; Boufous, S.; Bucello, C.; Burch, M.; Burney, P.; Carapetis, J.; Chen, H.; Chou, D.; Chugh, S.S.; Coffeng, L.E.; Colan, S.D.; Colquhoun, S.; Colson, K.E.; Condon, J.; Connor, M.D.; Cooper, L.T.; Corriere, M.; Cortinovis, M.; de Vaccaro, K.C.; Couser, W.; Cowie, B.C.; Criqui, M.H.; Cross, M.; Dabhadkar, K.C.; Dahodwala, N.; De Leo, D.; Degenhardt, L.; Delossantos, A.; Denenberg, J.; Des Jarlais, D.C.; Dharmaratne, S.D.; Dorsey, E.R.; Driscoll, T.; Duber, H.; Ebel, B.; Erwin, P.J.; Espindola, P.; Ezzati, M.; Feigin, V.; Flaxman, A.D.; Forouzanfar, M.H.; Fowkes, F.G.; Franklin, R.; Fransen, M.; Freeman, M.K.; Gabriel, S.E.; Gakidou, E.; Gaspari, F.; Gillum, R.F.; Gonzalez-Medina, D.; Halasa, Y.A.; Haring, D.; Harrison, J.E.; Havmoeller, R.; Hay, R.J.; Hoen, B.; Hotez, P.J.; Hoy, D.; Jacobsen, K.H.; James, S.L.; Jasrasaria, R.; Jayaraman, S.; Johns, N.; Karthikeyan, G.; Kassebaum, N.; Keren, A.; Khoo, J.P.; Knowlton, L.M.; Kobusingye, O.; Koranteng, A.; Krishnamurthi, R.; Lipnick, M.; Lipshultz, S.E.; Ohno, S.L.; Mabweijano, J.; MacIntyre, M.F.; Mallinger, L.; March, L.; Marks, G.B.; Marks, R.; Matsumori, A.; Matzopoulos, R.; Mayosi, B.M.; McAnulty, J.H.; McDermott, M.M.; McGrath, J.; Mensah, G.A.; Merriman, T.R.; Michaud, C.; Miller, M.; Miller, T.R.; Mock, C.; Mocumbi, A.O.; Mokdad, A.A.; Moran, A.; Mulholland, K.; Nair, M.N.; Naldi, L.; Narayan, K.M.; Nasseri, K.; Norman, P.; O'Donnell, M.; Omer, S.B.; Ortblad, K.; Osborne, R.; Ozgediz, D.; Pahari, B.; Pandian, J.D.; Rivero, A.P.; Padilla, R.P.; Perez-Ruiz, F.; Perico, N.; Phillips, D.; Pierce, K.; Pope, C.A. 3rd.; Porrini, E.; Pourmalek, F.; Raju, M.; Ranganathan, D.; Rehm, J.T.; Rein, D.B.; Remuzzi, G.; Rivara, F.P.; Roberts, T.; De Leon, F.R.; Rosenfeld, L.C.; Rushton, L.; Sacco, R.L.; Salomon, J.A.; Sampson, U.; Sanman, E.; Schwebel, D.C.; Segui-Gomez, M.; Shepard, D.S.; Singh, D.; Singleton, J.; Sliwa, K.; Smith, E.; Steer, A.; Taylor, J.A.; Thomas, B.; Tleyjeh, I.M.; Towbin, J.A.; Truelsen, T.; Undurraga, E.A.; Venketasubramanian, N.; Vijayakumar, L.; Vos, T.; Wagner, G.R.; Wang, M.; Wang, W.; Watt, K.; Weinstock, M.A.; Weintraub, R.; Wilkinson, J.D.; Woolf, A.D.; Wulf, S.; Yeh, P.H.; Yip, P.; Zabetian, A.; Zheng, Z.J.; Lopez, A.D.; Murray, C.J.; AlMazroa, M.A.; Memish, Z.A. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010. Lancet, 2012, 380, 2095-2128.
2. Adeyi, O.; Smith, O.; Robles, S. Public policy and the challenge of chronic noncommunicable diseases. Int. J. Epidemiol., 2008, 37, 686-687.
3. Hansson, G.K.; Hermansson, A. The immune system in atherosclerosis. Nat Immunol., 2011, 12, 204-212.
4. Libby, P.; Ridker, P.M.; Hansson, G.K. Progress and challenges in translating the biology of atherosclerosis. Nature, 2011, 473, 317-325.
5. Weber, C.; Noels, H. Atherosclerosis: current pathogenesis and therapeutic options. Nat. Med., 2011, 17, 1410-1222.
6. Schoenhagen, P.; McErlean, E.S.; Nissen, S.E. The vulnerable coronary plaque. J. Cardiovasc. Nurs., 2000, 15, 1-12.
7. Libby, P.; Okamoto, Y.; Rocha, V.Z.; Folco, E. Inflammation in atherosclerosis: Transition from theory to practice. Circ. J., 2010, 74, 213-220.
8. Lemaitre, B.; Nicolas, E.; Michaut, L.; Reichhart, J.M.; Hoffmann, J.A. The dorsoventral regulatory gene cassette spatzle/Toll/cactus controls the potent antifungal response in Drosophila adults. Cell, 1996, 86, 973-983.
9. Medzhitov, R.; Preston-Hurlburt, P.; Janeway, C.A. Jr. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature, 1997, 388, 394-397.
10. Laberge, M.A.; Moore, K.J.; Freeman, M.W. Atherosclerosis and innate immune signaling. Ann. Med., 2005, 37, 130-140.
11. Gay, N.J.; Gangloff, M. Structure and function of Toll receptors and their ligands. Annu. Rev. Biochem., 2007, 76, 141-165.
12. Frantz, S.; Ertl, G.; Bauersachs, J. Mechanisms of disease: Toll-like receptors in cardiovascular disease. Nat. Clin. Pract. Cardiovasc. Med., 2007, 4, 444-454.
13. Andersson, U.; Wang, H.; Palmblad, K.; Aveberger, A.C.; Bloom, O.; Erlandsson-Harris, H.; Janson, A.; Kokkola, R.; Zhang, M.; Yang, H.; Tracey, K.J. High mobility group 1 protein (HMG-1) stimulates proinflammatory cytokine synthesis in human monocytes. J. Exp. Med., 2000, 192, 565-570.
14. Kawai, T.; Akira, S. Toll-like receptors and their crosstalk with other innate receptors in infection and immunity. Immunity, 2011, 34, 637-650.
15. Kira, S.; Uematsu, S.; Takeuchi, O. Pathogen recognition and innate immunity. Cell, 2006, 124, 783-801.
16. Godfroy, J.I. 3rd.; Roostan, M.; Moroz, Y.S.; Korendovych, I.V.; Yin, H. Isolated Toll-like receptor transmembrane domains are capable of oligomerization. PLoS One, 2012, 7, e48875.
17. Leonard, J.N.; Bell, J.K.; Segal, D.M. Predicting Toll-like receptor structures and characterizing ligand binding. Methods Mol. Biol., 2009, 517, 55-67.
18. Bell, J.K.; Botos, I.; Hall, P.R.; Askins, J.; Shiloach, J.; Davies, D.R.; Segal, D.M. The molecular structure of the TLR3 extracellular domain. J. Endotoxin Res., 2006, 12, 375-378.
19. Willcocks, S.; Offord, V.; Seyfert, H.M.; Coffey, T.J.; Werling, D. Species-specific PAMP recognition by TLR2 and evidence for species-restricted interaction with Dectin-1. J. Leukoc. Biol., 2013, 94, 449-458.
20. Matsushima, N.; Miyashita, H.; Mikami, T.; Kuroki, Y. A nested leucine rich repeat (LRR) domain: the precursor of LRRs is a ten or eleven residue motif. BMC Microbiol., 2010, 10, 235.
21. Kajava, A.V. Structural diversity of leucine-rich repeat proteins. J. Mol. Biol., 1998, 277, 519-527.
22. Kobe, B., Kajava, A.V. The leucine-rich repeat as a protein recognition motif. Curr. Opin. Struct. Biol., 2001, 11, 725-732.
23. Wei, T.; Gong, J.; Jamitzky, F.; Heckl, W.M.; Stark, R.W, Roessle, S.C. LRRML: a conformational database and an XML description of leucine-rich repeats (LRRs). BMC Struct. Biol., 2008, 8, 47.
24. Matsushima, N.; Tanaka, T.; Enkhbayar, P.; Mikami, T.; Taga, M.; Yamada, K.; Kuroki, Y. Comparative sequence analysis of leucine-rich repeats (LRRs) within vertebrate toll-like receptors. BMC Genomics, 2007, 8, 124.
25. Lu, X.; Kakkar, V. Inflammasome and atherogenesis. Curr. Pharm. Des., 2014, 20, 108-124.
26. Gay, N.J.; Packman, L.C.; Weldon, M.A.; Barna, J.C. A leucine-rich repeat peptide derived from the Drosophila Toll receptor forms extended filaments with a beta-sheet structure. FEBS Lett., 1991, 291, 87-91.
27. Rothberg, J.M.; Jacobs, J.R.; Goodman, C.S.; Artavanis-Tsakonas, S. slit: an extracellular protein necessary for development of midline glia and commissural axon pathways contains both EGF and LRR domains. Genes Dev., 1990, 4, 2169-2187.
28. Kobe, B.; Deisenhofer, J. A structural basis of the interactions between leucine-rich repeats and protein ligands. Nature, 1995, 374, 183-186.
29. Tan, X.; Calderon-Villalobos. L.I.; Sharon, M.; Zheng, C.; Robinson, C.V.; Estelle, M.; Zheng, N. Mechanism of auxin perception by the TIR1 ubiquitin ligase. Nature, 2007, 446, 640-645.
30. Hayashi, K.; Tan, X.; Zheng, N.; Hatate, T.; Kimura, Y.; Kepinski, S.; Nozaki, H. Small molecule agonists and antagonists of F-box protein-substrate interactions in auxin perception and signalling. Proc. Natl. Acad. Sci. USA., 2008, 105, 5632-5637.
31. Sheard, L.B.; Tan, X.; Mao, H.; Withers, J.; Ben-Nissan, G.; Hinds, T.R.; Kobayashi, Y.; Hsu, F.F.; Sharon, M.; Browse, J.; He, S.Y.; Rizo, J.; Howe, G.A.; Zheng, N.; Jasmonate perception by inositol-phosphate-potentiated COI1-JAZ co-receptor. Nature, 2010, 468, 400-405.
32. Barton, G.M.; Kagan, J.C.; Medzhitov, R. Intracellular localization of Toll-like receptor 9 prevents recognition of self DNA but facilitates access to viral DNA. Nat. Immunol., 2006, 7, 49-56.
33. Kenny, E.F. Signalling adaptors used by Toll-like receptors. An update. Cytokin, 2008, 43, 342-349.
34. Kumeta, H.; Sakakibara, H.; Enokizono, Y.; Ogura, K.; Horiuchi, M.; Matsumoto, M.; Seya, T.; Inagaki, F. The N-terminaldomain of TIR domain-containing adaptormolecule-1, TICAM-1. J. Biomol. NMR, 2014, 58, 227-320.
35. Enokizono, Y.; Kumeta, H.; Funami, K.; Horiuchi, M.; Sarmiento, J.; Yamashita, K.; Standley, D.M.; Matsumoto, M.; Seya, T.; Inagaki, F. Structures and interface mapping of the TIR domain-containing adaptor molecules involved in interferon signaling. Proc. Natl. Acad. Sci. USA, 2013, 110, 19908-19913.
36. Xu, Y.; Tao, X.; Shen, B.; Horng, T.; Medzhitov, R.; Manley, J.L.; Tong, L. Structural basis for signal transduction by the Toll/interleukin-1 receptor domains. Nature, 2000, 408, 111-115.
37. Choe, J.; Kelker, M.S.; Wilson, I.A. Crystal structure of human toll-like receptor 3 (TLR3) ectodomain. Science, 2005, 309, 581-585.
38. Fekonja, O.; Avbelj, M.; Jerala, R. Suppression of TLR signaling by targeting TIR domain-containing proteins. Curr. Protein Pept. Sci., 2012, 13, 776-788.
39. Li, C.; Zienkiewicz, J.; Hawiger, J. Interactive sites in the Myd88 Toll/interleukin (IL) 1 receptor domain responsible for coupling to the IL1b signaling pathway. J. Biol. Chem., 2005, 280, 26152-26159.
40. Vorkapic, E.; Lundberg, A.M.; Mayranpaa, M.I.; Eriksson, P.; Wagsater, D. TRIF adaptor signaling is important in abdominal aortic aneurysm formation. Atherosclerosis, 2015, 241, 561-568.
41. Liu, L.; Botos, I.; Wang, Y.; Leonard, J.N.; Shiloach, J.; Segal, D.M.; Davies, D.R. Structural basis of toll-like receptor 3 signaling with double-stranded RNA. Science, 2008, 320, 379-381.
42. O'Neill, L.A.; Bowie, A.G. The family of five: TIRdomain-containing adaptors in Toll-like receptor signalling. Nat. Rev. Immunol., 2007, 7, 353-364.
43. Nyman, T.; Stenmark, P.; Flodin, S.; Johansson, I.; Hammarstrom, M.; Nordlund, P. The crystal structure of the human toll-like receptor 10 cytoplasmic domain reveals a putative signaling dimer. J. Biol. Chem., 2008, 283, 11861-11865.
44. Khan, J.A.; Brint, E.K.; O'Neill, L.A.; Tong, L. Crystal structure of the Toll/interleukin-1 receptor domain of human IL-1RAPL. J. Biol. Chem., 2004, 279, 31664-31670.
45. Chan, S.L.; Mukasa, T.; Santelli, E.; Low, L.Y.; Pascual, J. The crystal structure of a TIR domain from Arabidopsis thaliana reveals a conserved helical region unique to plants. Protein Sci., 2010, 19, 155-161.
46. Snyder, G.A.; Deredge, D.; Waldhuber, A.; Fresquez, T.; Wilkins, D.Z.; Smith, P.T.; Durr, S.; Cirl, C.; Jiang, J.; Jennings, W.; Luchetti, T.; Snyder, N.; Sundberg, E.J.; Wintrode, P.; Miethke, T.; Xiao, T.S. Crystal structures of the Toll/Interleukin-1 receptor (TIR) domains from the Brucella protein TcpB and host adaptor TIRAP reveal mechanisms of molecular mimicry. J. Biol. Chem., 2014, 289, 669-679.
47. Ohnishi, H.; Tochio, H.; Kato, Z.; Orii, K.E.; Li, A.; Kimura, T.; Hiroaki, H.; Kondo, N. Shirakawa, M. Structural basis for the multiple interactions of the MyD88 TIR domain in TLR4 signaling. Proc. Natl. Acad. Sci. USA., 2009, 106, 10260-10265.
48. Cole, J.E.; Georgiou, E.; Monaco, C. The expression and functions of toll-like receptors in atherosclerosis. Mediators Inflamm., 2010, 2010, 393946.
49. de Kleijn, D.; Pasterkamp, G. Toll-like receptors in cardiovascular diseases. Cardiovasc. Res., 2003, 60, 58-67.
50. Boyd, J.H.; Mathur, S.; Wang, Y.; Bateman, R.M.; Walley, K.R. Toll-like receptor stimulation in cardiomyoctes decreases contractility and initiates an NF-kappaB dependent inflammatory response. Cardiovasc. Res., 2006, 72, 384-393.
51. Frantz, S.; Kelly, R.A.; Bourcier, T. Role of TLR-2 in the activation of nuclear factor kappaB by oxidative stress in cardiac myocytes. J. Biol. Chem., 2001, 276, 5197-5203.
52. Dunzendorfer, S.; Lee, H.K.; Tobias, P.S. Flow-dependent regulation of endothelial Toll-like receptor 2 expression through inhibition of SP1 activity. Circ. Res., 2004, 95, 684-691.
53. Abarbanell, A.M.; Wang, Y.; Herrmann, J.L.; Weil, B.R.; Poynter, J.A.; Manukyan, M.C.; Meldrum, D.R. Toll-like receptor 2 mediates mesenchymal stem cell-associated myocardial recovery and VEGF production following acute ischemia-reperfusion injury. Am. J. Physiol. Heart Circ. Physiol., 2010, 298, H1529-H1536.
54. Schnittker, D.; Kwofie, K.; Ashkar, A.; Trigatti, B.; Richards, C.D. Oncostatin M and TLR-4 ligand synergize to induce MCP-1, IL-6, and VEGF in human aortic adventitial fibroblasts and smooth muscle cells. Mediators Inflamm., 2013, 2013, 317503.
55. Xu, X.H.; Shah, P.K.; Faure, E.; Equils, O.; Thomas, L.; Fishbein, M.C.; Luthringer, D.; Xu, X.P.; Rajavashisth, T.B.; Yano, J.; Kaul, S.; Arditi, M. Toll-like receptor-4 is expressed by macrophages in murine and human lipid-rich atherosclerotic plaques and upregulated by oxidized LDL. Circulation, 2001, 104, 3103-3108.
56. Carneiro, A.B.; Iaciura, B.M.; Nohara, L.L.; Lopes, C.D.; Veas, E.M.; Mariano, V.S.; Bozza, P.T.; Lopes, U.G.; Atella, G.C.; Almeida, I.C.; Silva-Neto, M.A. Lysophosphatidylcholine triggers TLR2- and TLR4-mediated signaling pathways but counteracts LPS-induced NO synthesis in peritoneal macrophages by inhibiting NF-κB translocation and MAPK/ERK phosphorylation. PLoS One, 2013, 8, e76233.
57. Muzio, M.; Bosisio, D.; Polentarutti, N.; D'amico, G.; Stoppacciaro, A.; Mancinelli, R.; van't Veer, C.; Penton-Rol, G.; Ruco, L.P.; Allavena, P.; Mantovani, A. Differential expression and regulation of Toll-like receptors (TLR) in human leukocytes: selective expression of TLR3 in dendritic cells. J. Immunol., 2000, 164, 5998-6004.
58. Kadowaki, N.; Ho, S.; Antonenko, S.; Malefyt, R.W.; Kastelein, R.A.; Bazan, F.; Liu, Y.J. Subsets of human dendritic cell precursors express different Toll-like receptors and respond to different microbial antigens. J. Exp. Med., 2001, 194, 863-869.
59. Visintin, A.; Mazzoni, A.; Spitzer, J.H.; Wyllie, D.H.; Dower, S.K.; Segal, D.M. Regulation of Toll-like receptors in human monocytes and dendritic cells. J. Immunol., 2001, 166, 249-255.
60. Hornung, V.; Rothenfusser, S.; Britsch, S.; Krug, A.; Jahrsdorfer, B.; Giese, T.; Endres, S.; Hartmann, G. Quantitative expression of Toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides. J. Immunol., 2002, 168, 4531-4537.
61. Norata, G.D.; Garlaschelli, K.; Ongari, M.; Raselli, S.; Grigore, L.; Benvenuto, F.; Maggi, F.M.; Catapano, A.L. Effect of the Toll-like receptor 4 (TLR-4) variants on intima-media thickness and monocyte-derived macrophage response to LPS. J. Intern. Med., 2005, 258, 21-27.
62. Nijhuis, M.M.; Pasterkamp, G.; Sluis, N.I.; de Kleijn, D.P.; Laman, J.D.; Ulfman, L.H. Peptidoglycan increases firm adhesion of monocytes under flow conditions and primes monocyte chemotaxis. J. Vasc. Res., 2007, 44, 214-222.
63. Mizoguchi, E.; Orihara, K.; Hamasaki, S.; Ishida, S.; Kataoka, T.; Ogawa, M.; Saihara, K.; Okui, H.; Fukudome, T.; Shinsato, T.; Shirasawa, T.; Ichiki, H.; Kubozono, T.; Ninomiya, Y.; Otsuji, Y.; Tei, C. Association between Tolllike receptors and the extent and severity of coronary artery disease in patients with stable angina. Coron. Artery Dis., 2007, 18, 31-38.
64. Garin, A.; Meyer-Hermann, M.; Contie, M.; Figge, M.T.; Buatois, V.; Gunzer, M.; Toellner, K.M.; Elson, G.; Kosco-Vilbois, M.H. Toll-like receptor 4 signaling by follicular dendritic cells is pivotal for germinal center onset and affinity maturation. Immunity, 2010, 33, 84-95.
65. Ito, T.; Amakawa, R.; Kaisho, T.; Hemmi, H.; Tajima, K.; Uehira, K.; Ozaki, Y.; Tomizawa, H.; Akira, S.; Fukuhara, S. Interferon-α and interleukin-12 are induced differentially by Toll-like receptor 7 ligands in human blood dendritic cell subsets. J. Exp. Med., 2002, 195, 1507-1512.
66. Jarrossay, D.; Napolitani, G.; Colonna, M.; Sallusto, F.; Lanzavecchia, A. Specialization and complementarity in microbial molecule recognition by human myeloid and plasmacytoid dendritic cells. Eur. J. Immunol., 2001, 31, 3388-3393.
67. Matsumoto, M.; Funami, K.; Tanabe, M.; Oshiumi, H.; Shingai, M.; Seto, Y.; Yamamoto, A.; Seya, T. Subcellular localization of Toll-like receptor 3 in human dendritic cells. J. Immunol., 2003, 171, 3154-3162.
68. Erridge, C.; Webb, D.J.; Spickett, C.M. 25-Hydroxycholesterol, 7beta-hydroxycholesterol and 7-ketocholesterol upregulate interleukin-8 expression independently of Tolllike receptor 1, 2, 4 or 6 signalling in human macrophages. Free Radic. Res., 2007, 41, 260-266.
69. Eaves-Pyles, T.; Bu, H.F.; Tan, X.D.; Cong, Y.; Patel, J.; Davey, R.A.; Strasser, J.E. Luminal-applied flagellin is internalized by polarized intestinal epithelial cells and elicits immune responses via the TLR5 dependent mechanism. Plos One, 2011, 6, e24869.
70. Tracy, R.E.; Eigenbrodt, M.L. Coronary artery circumferential stress: departure from Laplace expectations with aging. Scientific World Journal, 2009, 9, 946-960.
71. Curtiss, L.K.; Black, A.S.; Bonnet, D.J.; Tobias, P.S. Atherosclerosis induced by endogenous and exogenous toll-like receptor (TLR)1 or TLR6 agonists. J. Lipid Res., 2012, 53, 2126-2132.
72. Brown, P.M.; Kennedy, D.J.; Morton, R.E.; Febbraio, M. CD36/SR-B2-TLR2 dependent pathways enhance Porphyromonas gingivalis mediated atherosclerosis in the Ldlr KO mouse model. PLoS One, 2015, 10, e0125126.
73. Schoneveld, A.H.; Hoefer, I.; Sluijter, J.P.; Laman, J.D.; de Kleijn, D.P.; Pasterkamp, G. Atheroscleroticlesion development and Toll like receptor 2 and 4 responsiveness. Atherosclerosis, 2008, 197, 95-104.
74. Methe, H.; Kim, J.O.; Kofler, S.; Weis, M.; Nabauer, M.; Koglin, J. Expansion of circulating Toll-likereceptor 4-positive monocytes in patients with acute coronary syndrome. Circulation, 2005, 111, 2654-2661.
75. Kuwahata, S.; Fujita, S.; Orihara, K.; Hamasaki, S.; Oba, R.; Hirai, H.; Nagata, K.; Ishida, S.; Kataoka, T.; Oketani, N.; Ichiki, H.; Iriki, Y.; Saihara, K.; Okui, H.; Ninomiya, Y.; Tei, C. High expression level of Toll-like receptor 2 on monocytes is an important risk factor for arteriosclerotic disease. Atherosclerosis, 2010, 209, 248-254.
76. Edfeldt, K.; Swedenborg, J.; Hansson, G.K.; Yan, Z.Q. Expression of toll-like receptors in human atherosclerotic lesions: a possible pathway for plaque activation. Circulation, 2002, 105, 1158-1161.
77. Mullick, A.E.; Soldau, K.; Kiosses, W.B.; Bell, T.A. 3rd.; Tobias, P.S.; Curtiss, L.K. Increased endothelial expression of Toll-like receptor 2 at sites of disturbed blood flow exacerbates early atherogenic events. J. Exp. Med., 2008, 205, 373-383.
78. Curtiss, L.K.; Tobias, P.S. Emerging role of Toll-like receptors in atherosclerosis. J. Lipid Res., 2009, 50(Suppl.), S340-S345.
79. Schoneveld, A.H.; Oude, Nijhuis, M.M.; van Middelaar, B.; Laman, J.D.; de Kleijn, D.P.; Pasterkamp, G. Toll-like receptor 2 stimulation induces intimal hyperplasia and atherosclerotic lesion development. Cardiovasc. Res., 2005, 66, 162-169.
80. Schoneveld, A.H.; Hoefer, I.; Sluijter, J.P.; Laman, J.D.; de Kleijn, D.P.; Pasterkamp, G. Atherosclerotic lesion development and Toll like receptor 2 and 4 responsiveness. Atherosclerosis, 2008, 197, 95-104.
81. Kirschning, C.J.; Schumann, R.R. TLR2: cellular sensor for microbial and endogenous molecular patterns. Curr. Top. Microbiol. Immunol., 2002, 270, 121-144.
82. Takeuchi, O.; Sato, S.; Horiuchi, T.; Hoshino, K.; Takeda, K.; Dong, Z.; Modlin, R.L.; Akira, S. Cutting edge: role of Toll-like receptor 1 in mediating immune response to microbial lipoproteins. J. Immunol., 2002, 169, 10-14.
83. Moghimpour, B.F.; Vallejo, J.G.; Rezaei, N. Toll-like receptor signaling pathways in cardiovascular diseases: challenges and opportunities. Int. Rev. Immunol., 2012, 31, 379-395.
84. Higashikuni, Y.; Tanaka, K.; Kato, M.; Nureki, O.; Hirata, Y.; Nagai, R.; Komuro, I.; Sata, M. Toll-like receptor-2 mediates adaptive cardiac hypertrophy in response to pressure overload through interleukin-1beta upregulation via nuclear factor kappaB activation. J. Am. Heart Assoc., 2013, 2, e000267.
85. Wang, L.; Li, Y.L.; Zhang, C.C.; Cui, W.; Wang, X.; Xia, Y.; Du, J.; Li, H.H. Inhibition of Toll-like receptor 2 reduces cardiac fibrosis by attenuating macrophage-mediated inflammation. Cardiovasc. Res., 2014, 101, 383-392.
86. Mullick, A.E.; Tobias, P.S.; Curtiss, L.K. Modulation of atherosclerosis in mice by toll-like receptor 2. J. Clin. Invest., 2005, 115, 3149-3156.
87. rd.; Genco, C.A. Toll-like receptor 2 plays a critical role in the progression of atherosclerosis that is independent of dietary lipids. Atherosclerosis, 2008, 196, 146-154.
88. Kirii, H.; Niwa, T.; Yamada, Y.; Wada, H.; Saito, K.; Iwakura, Y.; Asano, M.; Moriwaki, H.; Seishima, M. Lack of interleukin-1β decreases the severity of atherosclerosis in ApoE-deficient mice. Arterioscler. Thromb. Vasc. Biol., 2003, 23, 656-660.
89. Michelsen, K.S.; Wong, M.H.; Shah, P.K.; Zhang, W.; Yano, J.; Doherty, T.M.; Akira, S.; Rajavashisth, T.B.; Arditi, M. Lack of Toll-like receptor 4 or myeloid differentiation factor 88 reduces atherosclerosis and alters plaque phenotype in mice deficient in apolipoprotein E. Proc. Natl. Acad. Sci. USA., 2004, 101, 10679-10684.
90. Hoebe, K.; Georgel, P.; Rutschmann, S.; Du, X.; Mudd, S.; Crozat, K.; Sovath, S.; Shamel, L.; Hartung, T.; Zahringer, U.; Beutler, B. CD36 is a sensor of diacylglycerides. Nature, 2005, 433, 523-527.
91. Jimenez-Dalmaroni, M.J.; Xiao, N.; Corper, A.L.; Verdino, P.; Ainge, G.D.; Larsen, D.S.; Painter, G.F.; Rudd, P.M.; Dwek, R.A.; Hoebe, K.; Beutler, B.; Wilson, I.A. Soluble CD36 ectodomain binds negatively charged diacylglycerol ligands and acts as a co-receptor for TLR2. PLoS One, 2009, 4, e7411.
92. Houssen, M.E.; El-Mahdy, R.H.; Shahin, D.A. Serum soluble toll-like receptor 2: a novel biomarker for systemic lupus erythematosus disease activity and lupus-related cardiovascular dysfunction. Int. J. Rheum. Dis., 2014, doi: 10.1111/1756-185X.12452. [Epub ahead of print]
93. Cole, J.E.; Navin, T.J.; Cross, A.J.; Goddard, M.E.; Alexopoulou, L.; Mitra, A.T.; Davies, A.H.; Flavell, R.A.; Feldmann, M.; Monaco, C. Unexpected protective role for Toll-like receptor 3 in the arterial wall. Proc. Natl. Acad. Sci. USA., 2011, 108, 2372-2377.
94. Richards, M.R.; Black, A.S.; Bonnet, D.J.; Barish, G.D.; Woo, C.W.; Tabas, I.; Curtiss, L.K.; Tobias, P.S. The LPS2 mutation in TRIF is atheroprotective in hyperlipidemic low densitylipoprotein receptor knockout mice. Innate Immun., 2013, 19, 20-29.
95. Ishibashi, M.; Sayers, S.; D'Armiento, J.M.; Tall, A.R.; Welch, C.L. TLR3 deficiency protects against collagen degradation and medial destruction in murine atherosclerotic plaques. Atherosclerosis, 2013, 229, 52-61.
96. Zimmer, S.; Steinmetz, M.; Asdonk, T.; Motz, I.; Coch, C.; Hartmann, E.; Barchet, W.; Wassmann, S.; Hartmann, G.; Nickenig, G. Activation of endothelial toll-like receptor 3 impairs endothelial function. Circ. Res., 2011, 108, 1358-1366.
97. Lundberg, A.M.; Ketelhuth, D.F.; Johansson, M.E.; Gerdes, N.; Liu, S.; Yamamoto, M.; Akira, S.; Hansson, G.K. Tolllike receptor 3 and 4 signalling through the TRIF and TRAM adaptors in haematopoietic cells promotes atherosclerosis. Cardiovasc. Res., 2013, 99, 364-373.
98. Gatheral, T.; Reed, D.M.; Moreno, L.; Gough, P.J.; Votta, B.J.; Sehon, C.A.; Rickard, D.J.; Bertin, J.; Lim, E.; Nicholson, A.G.; Mitchell, J.A. A key role for the endothelium in NOD1 mediated vascular inflammation: comparison to TLR4 responses. PLoS One, 2012, 7, e42386.
99. Paul-Clark, M.J.; George, P.M.; Gatheral, T.; Parzych, K.; Wright, W.R.; Crawford, D.; Bailey, L.K.; Reed, D.M.; Mitchell, J.A. Pharmacology and therapeutic potential of pattern recognition receptors. Pharmacol. Ther., 2012, 135, 200-215.
100. Stewart, C.R.; Stuart, L.M.; Wilkinson, K.; van Gils, J.M.; Deng, J.; Halle, A.; Rayner, K.J.; Boyer, L.; Zhong, R.; Frazier, W.A.; Lacy-Hulbert, A.E.I.; Khoury, J.; Golenbock, D.T.; Moore, K.J. CD36 ligands promote sterile inflammation through assembly of a Toll-like receptor 4 and 6 heterodimer. Nat. Immunol., 2010, 11, 155-161.
101. Biragyn, A.; Ruffini, P.A.; Leifer, C.A.; Klyushnenkova, E.; Shakhov, A.; Chertov, O.; Shirakawa, A.K.; Farber, J.M.; Segal, D.M.; Oppenheim, J.J.; Kwak, L.W. Toll-like receptor 4-dependent activation of dendritic cells by betadefensin 2. Science, 2002, 298, 1025-1029.
102. Chen, S.; Wong, M.H.; Schulte, D.J.; Arditi, M.; Michelsen, K.S. Differential expression of toll-like receptor 2 (TLR2) and responses to TLR2 ligands between human and murine vascular endothelial cells. J. Endotoxin Res., 2007, 13, 281-296.
103. Vink, A.; Schoneveld, A.H.; van der Meer, J.J.; van Middelaar, B.J.; Sluijter, J.P.; Smeets, M.B.; Quax, P.H.; Lim, S.K.; Borst, C.; Pasterkamp, G.; de Kleijn, D.P. In vivo evidence for a role of toll-like receptor 4 in the development of intimal lesions. Circulation, 2002, 106, 1985-1990.
104. Coenen, K.R.; Gruen, M.L.; Lee-Young, R.S.; Puglisi, M.J.; Wasserman, D.H.; Hasty, A.H. Impact of macrophage Tolllike receptor 4 deficiency on macrophage infiltration into adipose tissue and the artery wall in mice. Diabetologia, 2009, 52, 318-328.
105. Tacke, F.; Alvarez, D.; Kaplan, T.J.; Jakubzick, C.; Spanbroek, R.; Llodra, J.; Garin, A.; Liu, J.; Mack, M.; van Rooijen, N.; Lira, S.A.; Habenicht, A.J.; Randolph, G.J. Monocyte subsets differentially employ CCR2, CCR5, and CX3CR1 to accumulate within atherosclerotic plaques. J. Clin. Invest., 2007, 117, 185-194.
106. Combadiere, C.; Potteaux, S.; Rodero, M.; Simon, T.; Pezard, A.; Esposito, B.; Merval, R.; Proudfoot, A.; Tedgui, A.; Mallat, Z. Combined inhibition of CCL2, CX3CR1, and CCR5 abrogates Ly6C(hi) and Ly6C(Lo) monocytosis and almost abolishes atherosclerosis in hypercholesterolemic mice. Circulation, 2008, 117, 1649-1657.
107. Chavez-Sanchez, L.; Garza-Reyes, M.G.; Espinosa-Luna, J.E.; Chavez-Rueda, K.; Legorreta-Haquet, M.V.; Blanco-Favela, F. The role of TLR2, TLR4 and CD36 in macrophage activation and foam cell formation in response to oxLDL in humans. Hum. Immunol., 2014, 75, 322-329.
108. Mita, Y.; Dobashi, K.; Endou, K.; Kawata, T.; Shimizu, Y.; Nakazawa, T.; Mori, M. Toll-like receptor 4 surface expression on human monocytes and B cells is modulated by IL-2 and IL-4. Immunol. Lett., 2002, 81, 71-75.
109. Hollestelle, S.C.; De Vries, M.R.; Van Keulen, J.K.; Schoneveld, A.H.; Vink, A.; Strijder, C.F.; Van Middelaar, B.J.; Pasterkamp, G.; Quax, P.H.; De Kleijn, D.P. Toll-like receptor 4 is involved in outward arterial remodeling. Circulation, 2004, 109, 393-398.
110. Bjorkbacka, H. Multiple roles of Toll-like receptor signalling in atherosclerosis. Curr. Opin. Lipidol., 2006, 17, 527-533.
111. Kim, J.S.; Park, D.W.; Lee, H.K.; Kim, J.R.; Baek, S.H. Early growth response-1 is involved in foam cell formation and is upregulated by the TLR9-MyD88-ERK1/2 pathway. Biochem. Biophys. Res. Commun., 2009, 390, 196-200.
112. Lee, J.; Lim, E.; Park, D.; Lee, S.; Kim, J.; Baek, S. A combination of Lox-1 and Nox1 regulates TLR9-mediated foam cell formation. Cell Signal, 2008, 20, 2266-2275.
113. Lee, S.J.; Choi, E.K.; Seo, K.W.; Bae, J.U.; Park, S.Y.; Kim, C.D. TLR4-mediated expression of Mac-1 in monocytes plays a pivotal role in monocyte adhesion to vascular endothelium. PLoS One, 2014, 9, e104588.
114. Oiknine, J.; Aviram, M. Increased susceptibility to activation and increased uptake of low density lipoprotein by cholesterol-loaded macrophages. Arterioscler. Thromb., 1992, 12, 745-753.
115. Naiki, Y.; Sorrentino, R.; Wong, M.H.; Michelsen, K.S.; Shimada, K.; Chen, S.; Yilmaz, A.; Slepenkin, A.; Schroder, N.W.; Crother, T.R.; Bulut, Y.; Doherty, T.M.; Bradley, M.; Shaposhnik, Z.; Peterson, E.M.; Tontonoz, P.; Shah, P.K.; Arditi, M. TLR/MyD88 and liver X receptor α signaling pathways reciprocally control Chlamydia pneumoniae-induced acceleration of atherosclerosis. J. Immunol., 2008, 181, 7176-7185.
116. Cao, F.; Castrillo, A.; Tontonoz, P.; Re, F.; Byrne, GI. Chlamydia pneumoniae-induced macrophage foam cell formation is mediated by Toll-like receptor 2. Infect. Immun., 2007, 75, 753-759.
117. Chen, S.; Sorrentino, R.; Shimada, K.; Bulut, Y.; Doherty, T.M.; Crother, T.R.; Arditi, M. Chlamydia pneumoniaeinduced foam cell formation requires MyD88-dependent and -independent signaling and is reciprocally modulated by liver X receptor activation. J. Immunol., 2008, 18, 7186-7193.
118. Karper, J.C.; Ewing, M.M.; de Vries, M.R.; de Jager, S.C.; Peters, E.A.; de Boer, H.C.; van Zonneveld, A.J.; Kuiper, J.; Huizinga, E.G.; Brondijk, T.H.; Jukema, J.W.; Quax, P.H. TLR accessory molecule RP105 (CD180) is involved in post-interventional vascular remodeling and soluble RP105 modulates neointima formation. PLoS One, 2013, 8, e67923.
119. Divanovic, S.; Trompette, A.; Atabani, S.F.; Madan, R.; Golenbock, D.T.; Visintin, A.; Finberg, R.W.; Tarakhovsky, A.; Vogel, S.N.; Belkaid, Y.; Kurt-Jones, E.A.; Karp, C.L. Inhibition of TLR-4/MD-2 signaling by RP105/MD-1. J. Endotoxin Res., 2005, 11, 363-368.
120. Divanovic, S.; Trompette, A.; Atabani, S.F.; Madan, R.; Golenbock, D.T.; Visintin, A.; Finberg, R.W.; Tarakhovsky, A.; Vogel, S.N.; Belkaid, Y.; Kurt-Jones, E.A.; Karp, C.L. Negative regulation of Toll-like receptor 4 signaling by the Toll-like receptor homolog RP105. Nat. Immunol., 2005, 6, 571-578.
121. Choi, S.; Harkewicz, R.; Lee, J.H.; Boullier, A.; Almazan, F.; Li, A.C.; Witztum, J.L.; Bae, Y.S.; Miller, Y.I. Lipoprotein accumulation in macrophages via Toll-like receptor-4-dependent fluid phase uptake. Circ. Res., 2009, 104, 1355-1363.
122. Doyle, S.; O'Connell, R.M.; Miranda, G.A., Vaidya, S.A.; Chow, E.K.; Liu, P.T.; Suzuki, S.; Suzuki, N.; Modlin, R.L.; Yeh, W.C.; Lane, T.F.; Cheng, G. Toll-like receptors induce a phagocytic gene program through p38. J. Exp. Med., 2004, 199, 81-90.
123. Castrillo, A.; Joseph, S.; Vaidya, S.A.; Haberland, M.; Fogelman, A.M.; Cheng, G.; Tontonoz, P. Crosstalk between LXR and Toll-like receptor signaling mediates bacterial and viral antagonism of cholesterol metabolism. Mol. Cell, 2003, 12, 805-816.
124. Irvine, K.L.; Hopkins, L.J.; Gangloff, M.; Bryant, C.E. The molecular basis for recognition of bacterial ligands at equine TLR2, TLR1 and TLR6. Vet. Res., 2013, 44, 50.
125. Jin, M.; Kim, S.; Heo, J.; Lee, M.; Kim, H.; Paik, S.; Lee, H.; Lee, J. Crystal structure of the TLR1-TLR2 heterodimer induced by binding of a tri-acylated lipopeptide. Cell, 2007, 130, 1071-1082.
126. Meng, Y.; Chen, C.; Wang, L.; Wang, X.; Tian, C.; Du, J.; Li, H.H. Toll-like receptor-2 ligand peptidoglycan upregulates expression and ubiquitin ligase activity of CHIP through JNK pathway. Cell Physiol. Biochem., 2013, 32, 1097-1105.
127. Carrouel, F.; Staquet, M.J.; Keller, J.F.; Baudouin, C.; Msika, P.; Bleicher, F.; Alliot-Licht, B.; Farges, J.C. Lipopolysaccharide-binding protein inhibits toll-like receptor 2 activation by lipoteichoic acid in human odontoblastlike cells. J. Endod., 2013, 39, 1008-1014.
128. Lim, R.; Barker, G.; Lappas, M. The TLR2 ligand FSL-1 and the TLR5 ligand Flagellin mediate pro-inflammatory and pro-labour response via MyD88/TRAF6/NF-κBdependent signalling. Am. J. Reprod. Immunol., 2014, 71, 401-417.
129. Drage, M.G.; Tsai, H.C.; Pecora, N.D.; Cheng, T.Y.; Arida, A.R.; Shukla, S.; Rojas, R.E.; Seshadri, C.; Moody, D.B.; Boom, W.H.; Sacchettini, J.C.; Harding, C.V. Mycobacterium tuberculosis lipoprotein LprG (Rv1411c) binds triacylated glycolipid agonists of Toll-like receptor 2. Nat. Struct. Mol. Biol., 2010, 17, 1088-1095.
130. Kang, J.; Nan, X.; Jin, M.; Youn, S.; Ryu, Y.; Mah, S.; Han, S.; Lee, H.; Paik, S.; Lee, J: Recognition of lipopeptide patterns by Toll-like receptor 2-Toll-like receptor 6 heterodimer. Immunity, 2009, 31, 873-884.
131. Schreiner, J.; Kretschmer, D.; Klenk, J.; Otto, M.; Buhring, H.J.; Stevanovic, S.; Wang, J.M.; Beer-Hammer, S.; Peschel, A.; Autenrieth, S.E. Staphylococcus aureus phenolsoluble modulin peptides modulate dendritic cell functions and increase in vitro priming of regulatory T cells. J. Immunol., 2013, 190, 3417-3426.
132. Jimenez-Dalmaroni, M.J.; Radcliffe, C.M.; Harvey, D.J.; Wormald, M.R.; Verdino, P.; Ainge, G.D.; Larsen, D.S.; Painter, G.F.; Ulevitch, R.; Beutler, B.; Rudd, P.M.; Dwek, R.A.; Wilson, I.A. Soluble human TLR2 ectodomain binds diacylglycerol from microbial lipopeptides and glycolipids. Innate Immun., 2015, 21, 175-193.
133. Lien, E.; Sellati, T.J.; Yoshimura, A.; Flo, T.H.; Rawadi, G.; Finberg, R.W.; Carroll, J.D.; Espevik, T.; Ingalls, R.R.; Radolf, J.D.; Golenbock, D.T. Toll-like receptor 2 functions as a pattern recognition receptor for diverse bacterial products. J. Biol. Chem., 1999, 274, 33419-33425.
134. Luhrmann, A.; Grote, K.; Stephan, M.; Tschernig, T.; Pabst, R. Local pulmonary immune stimulation by the Toll-like receptor 2 and 6 ligand MALP-2 in rats is age dependent. Immunol. Lett., 2007, 108, 167-173.
135. Nishiguchi, M.; Matsumoto, M.; Takao, T.; Hoshino, M.; Shimonishi, Y.; Tsuji, S.; Begum, N.A.; Takeuchi, O.; Akira, S.; Toyoshima, K.; Seya, T. Mycoplasma fermentans lipoprotein M161Ag-induced cell activation is mediated by Toll-like receptor 2: role of N-terminal hydrophobic portion in its multiple functions. J. Immunol., 2001, 166, 2610-2616.
136. Ribeiro, C.M.; Hermsen, T.; Taverne-Thiele, A.J.; Savelkoul, H.F.; Wiegertjes, G.F. Evolution of recognition of ligands from Gram-positive bacteria: similarities and differences in the TLR2-mediated response between mammalian vertebrates and teleost fish. J. Immunol., 2010, 184, 2355-2368.
137. Giambartolomei, G.H.; Zwerdling, A.; Cassataro, J.; Bruno, L.; Fossati, C.A.; Philipp, M.T. Lipoproteins, not lipopolysaccharide, are the key mediators of the proinflammatory response elicited by heat-killed Brucella abortus. J. Immunol., 2004, 173, 4635-4642.
138. Krishnegowda, G.; Hajjar, A.M.; Zhu, J.; Douglass, E.J.; Uematsu, S.; Akira, S.; Woods, A.S.; Gowda, D.C. Induction of proinflammatory responses in macrophages by the glycosylphosphatidylinositols of Plasmodium falciparum: cell signaling receptors, glycosylphosphatidylinositol (GPI) structural requirement, and regulation of GPI activity. J. Biol. Chem., 2005, 280, 8606-8616.
139. Pore, D.; Mahata, N.; Chakrabarti, M.K. Outer membrane protein A (OmpA) of Shigella flexneri 2a links innate and adaptive immunity in a TLR2-dependent manner and involvement of IL-12 and nitric oxide. J. Biol. Chem., 2012, 287, 12589-12601.
140. Bsibsi, M.; Bajramovic, J.J.; Van Duijvenvoorden, E.; Persoon, C.; Ravid, R.; Van Noort, J.M.; Vogt, M.H. Identification of soluble CD14 as an endogenous agonist for Tolllike receptor 2 on human astrocytes by genome-scale functional screening of glial cell derived proteins. Glia, 2007, 55, 473-482.
141. Vivarini Ade, C.; Pereira Rde, M.; Teixeira, K.L.; Calegari-Silva, T.C.; Bellio, M.; Laurenti, M.D.; Corbett, C.E.; Gomes, C.M.; Soares, R.P.; Silva, A.M.; Silveira, F.T.; Lopes, U.G. Human cutaneous leishmaniasis: interferon-dependent expression of double-stranded RNA-dependent protein kinase (PKR) via TLR2. FASEB J., 2011, 25, 4162-4173.
142. Ainai, A.; Ichinohe, T.; Tamura, S.; Kurata, T.; Sata, T.; Tashiro, M.; Hasegawa, H. Zymosan enhances the mucosal adjuvant activity of poly(I:C) in a nasal influenza vaccine. J. Med. Virol., 2010, 82, 476-484.
143. Sawa, Y.; Takata, S.; Hatakeyama, Y.; Ishikawa, H.; Tsuruga, E. Expression of toll-like receptor 2 in glomerular endothelial cells and promotion of diabetic nephropathy by Porphyromonas gingivalis lipopolysaccharide. PLoS One, 2014, 9, e97165.
144. Crane, D.D.; Ireland, R.; Alinger, J.B.; Small, P.; Bosio, C.M. Lipids derived from virulent Francisella tularensis broadly inhibit pulmonary inflammation via toll-like receptor 2 and peroxisome proliferator-activated receptor α. Clin. Vaccine Immunol., 2013, 20, 1531-1540.
145. Glasser, S.W.; Witt, T.L.; Senft, A.P.; Baatz, J.E.; Folger, D.; Maxfield, M.D.; Akinbi, H.T.; Newton, D.A.; Prows, D.R.; Korfhagen, T.R. Surfactant protein C-deficient mice are susceptible to respiratory syncytial virus infection. Am. J. Physiol. Lung Cell Mol. Physiol., 2009, 297, L64-L72.
146. Kulka, M.; Alexopoulou, L.; Flavell, R.A.; Metcalfe, D.D. Activation of mast cells by double-stranded RNA: evidence for activation through Toll-like receptor 3. J. Allergy Clin. Immunol., 2004, 114, 174-182.
147. Cyr, S.L.; Angers, I.; Guillot, L.; Stoica-Popescu, I.; Lussier, M.; Qureshi, S.; Burt, D.S.; Ward, B.J. TLR4 and MyD88 control protection and pulmonary granulocytic recruitment in a murine intranasal RSV immunization and challenge model. Vaccine, 2009, 27, 421-430.
148. van Keulen, J.K.; de Kleijn, D.P.; Nijhuis, M.M.; Busser, E.; Velema, E.; Fijnheer, R.; van der Graaf, Y.; Moll, F.L.; de Vries, J.P.; Pasterkamp, G. Levels of extra domain A containing fibronectin in human atherosclerotic plaques are associated with a stable plaque phenotype. Atherosclerosis, 2007, 195, e83-e91.
149. Lasarte, J.J.; Casares, N.; Gorraiz, M.; Hervas-Stubbs, S.; Arribillaga, L.; Mansilla, C.; Durantez, M.; Llopiz, D.; Sarobe, P.; Borras-Cuesta, F.; Prieto, J.; Leclerc, C. The extra domain A from fibronectin targets antigens to TLR4-expressing cells and induces cytotoxic T cell responses in vivo. J. Immunol., 2007, 178, 748-756.
150. Iwata, Y.; Yoshizaki, A.; Komura, K.; Shimizu, K.; Ogawa, F.; Hara, T.; Muroi, E.; Bae, S.; Takenaka, M.; Yukami, T.; Hasegawa, M.; Fujimoto, M.; Tomita, Y.; Tedder, T.F.; Sato, S. CD19, a response regulator of B lymphocytes, regulates wound healing through hyaluronan-induced TLR4 signaling. Am. J. Pathol., 2009, 175, 649-660.
151. Cui, W.; Joshi, N.S.; Liu, Y.; Meng, H.; Kleinstein, S.H.; Kaech, S. TLR4 ligands lipopolysaccharide and monophosphoryl lipid a differentially regulate effector and memory CD8+ T Cell differentiation. J. Immunol., 2014, 1929, 4221-4232.
152. Parkunan, S.M.; Astley, R.; Callegan, M.C. Role of TLR5 and flagella in bacillus intraocular infection. PLoS One, 2014, 9, e100543.
153. Cunningham, A.L.; Dang, K.M.; Yu, J.J.; Guentzel, M.N.; Heidner, H.W.; Klose, K.E.; Arulanandam, B.P. Enhancement of vaccine efficacy by expression of a TLR5 ligand in the defined live attenuated Francisella tularensis subsp. novicida strain U112ΔiglB::fljB. Vaccine, 2014, 32, 5234-5240.
154. Buwitt-Beckmann, U.; Heine, H.; Wiesmuller, K.H.; Jung, G.; Brock, R.; Akira, S.; Ulmer, A.J. TLR1- and TLR6-independent recognition of bacterial lipopeptides. J. Biol. Chem., 2006, 281, 9049-9057.
155. Colak, E.; Leslie, A.; Zausmer, K.; Khatamzas, E.; Kubarenko, A.V.; Pichulik, T.; Klimosch, S.N.; Mayer, A.; Siggs, O.; Hector, A.; Fischer, R.; Klesser, B.; Rautanen, A.; Frank, M.; Hill, A.V.; Manoury, B.; Beutler, B.; Hartl, D.; Simmons, A.; Weber, A.N. RNA and imidazoquinolines are sensed by distinct TLR7/8 ectodomain sites resulting in functionally disparate signaling events. J. Immunol., 2014, 192, 5963-5973.
156. Kaiser, S.; Rimbach, K.; Eigenbrod, T.; Dalpke, A.H.; Helm, M. A modified dinucleotide motif specifies tRNA recognition by TLR7. RNA, 2014, 20, 1351-1355.
157. Heil, F.; Hemmi, H.; Hochrein, H.; Ampenberger, F.; Kirschning, C.; Akira, S.; Lipford, G.; Wagner, H.; Bauer, S. Species-specific recognition of single-stranded RNA via Toll-like receptor 7 and 8. Science, 2004, 303, 1526-1529.
158. Riggio, M.P.; Lappin, D.F.; Bennett, D. Bacteria and Tolllike receptor and cytokine mRNA expression profiles associated with canine arthritis. Vet. Immunol. Immunopathol., 2014, 160, 158-166.
159. Schwab, L.; Goroncy, L.; Palaniyandi, S.; Gautam, S.; Triantafyllopoulou, A.; Mocsai, A.; Reichardt, W.; Karlsson, F.J.; Radhakrishnan, S.V.; Hanke, K.; Schmitt-Graeff, A.; Freudenberg, M.; von Loewenich, F.D.; Wolf, P.; Leonhardt, F.; Baxan, N.; Pfeifer, D.; Schmah, O.; Schonle, A.; Martin, S.F.; Mertelsmann, R.; Duyster, J.; Finke, J.; Prinz, M.; Henneke, P.; Hacker, H.; Hildebrandt, G.C.; Hacker, G.; Zeiser, R. Neutrophil granulocytes recruited upon translocation of intestinal bacteria enhance graft-versus-host disease via tissue damage. Nat. Med., 2014, 20, 648-654.
160. Cervantes, J.L.; La Vake, C.J.; Weinerman, B.; Luu, S.; O'Connell, C.; Verardi, P.H.; Salazar, J.C. Human TLR8 is activated upon recognition of Borrelia burgdorferi RNA in the phagosome of human monocytes. J. Leukoc. Biol., 2013, 94, 1231-1241.
161. Hsu, K.; Chung, Y.M.; Endoh, Y.; Geczy, C.L. TLR9 Ligands induce S100A8 in macrophages via a STAT3-dependent pathway which requires IL-10 and PGE2. PLoS One, 2014, 9, e103629.
162. Ghamlouch, H.; Ouled-Haddou, H.; Guyart, A.; Regnier, A.; Trudel, S.; Claisse, J.F.; Fuentes, V.; Royer, B.; Marolleau, J.P.; Gubler, B. TLR9 Ligand (CpG oligodeoxynucleotide) induces CLL B-Cells to differentiate into CD20(+) antibody-secreting Cells. Front Immunol., 2014, 5, 292.
163. Govindaraj, R.G.; Manavalan, B.; Lee, G.; Choi, S. Molecular modeling-based evaluation of hTLR10 and identification of potential ligands in Toll-like receptor signaling. PLoS One, 2010, 5, e12713.
164. Yarovinsky, F.; Zhang, D.; Andersen, J.F.; Bannenberg, G.L.; Serhan, C.N.; Hayden, M.S.; Hieny, S.; Sutterwala, F.S.; Flavell, R.A.; Ghosh, S.; Sher, A. TLR11 activation of dendritic cells by a protozoan profilin-like protein. Science, 2005, 308, 1626-1629.
165. Koblansky, A.A.; Jankovic, D.; Oh, H.; Hieny, S.; Sungnak, W.; Mathur, R.; Hayden, M.S.; Akira, S.; Sher, A.; Ghosh, S. Recognition of profilin by Toll-like receptor 12 is critical for host resistance to Toxoplasma gondii. Immunity, 2012, 38, 119-130.
166. Shi, Z.; Cai, Z.; Sanchez, A.; Zhang, T.; Wen, S.; Wang, J.; Yang, J.; Fu, S.; Zhang, D. A novel Toll-like receptor that recognizes vesicular stomatitis virus. J. Biol. Chem., 2011, 286, 4517-4524.
167. Oldenburg, M.; Kruger, A.; Ferstl, R.; Kaufmann, A.; Nees, G.; Sigmund, A.; Bathke, B.; Lauterbach, H.; Suter, M.; Dreher, S.; Koedel, U.; Akira, S.; Kawai, T.; Buer, J.; Wagner, H.; Bauer, S.; Hochrein, H.; Kirschning, C.J. TLR13 recognizes bacterial 23S rRNA devoid of erythromycin resistance-forming modification. Science, 2012, 337, 1111-1115.
168. Hwang, S.D.; Kondo, H.; Hirono, I.; Aoki, T. Molecular cloning and characterization of Toll-like receptor 14 in Japanese flounder, Paralichthys olivaceus. Fish Shellfish. Immunol., 2011, 30, 425-429.
169. Golovkin, A.S.; Ponasenko, A.V.; Khutornaya, M.V.; Kutikhin, A.G.; Salakhov, R.R.; Yuzhalin, A.E.; Zhidkova, I.I.; Barbarash, O.L.; Barbarash, L.S. Association of TLR and TREM-1 gene polymorphisms with risk of coronary artery disease in a Russian population. Gene, 2014, 550,101-109.
170. Kiechl, S.; Lorenz, E.; Reindl, M.; Wiedermann, C.J.; Oberhollenzer, F.; Bonora, E.; Willeit, J.; Schwartz, D.A. Toll-like receptor 4 polymorphisms and atherogenesis. N. Engl. J. Med., 2002, 347, 185-192.
171. Hamann, L.; Koch, A.; Sur, S.; Hoefer, N.; Glaeser, C.; Schulz, S.; Gross, M.; Franke, A.; Nothlings, U.; Zacharowski, K.; Schumann, R.R. Association of a common TLR-6 polymorphism with coronary artery disease-implications for healthy ageing? Immun. Ageing, 2013, 10, 43.
172. Doddapattar, P.; Gandhi, C.; Prakash, P.; Dhanesha, N.; Grumbach, I.M.; Dailey, M.E.; Lentz, S.R.; Chauhan, A.K. Fibronectin splicing variants containing extra domain A promote atherosclerosis in mice through Toll-Like receptor 4. Arterioscler. Thromb. Vasc. Biol., 2015, 35, 2391-2400.
173. Jager, S.C. de.; Puijvelde, G.H.; Anes, A.A.; Bot, M.; Asbach, M.; Habets, K.L.; Foks, A.C.; Pasterkamp, G.; van der Poll, T.; Kuiper, J. Leukocyte TLR5 deficiency inhibits atherosclerosis by reduced macrophage recruitment and defective T Cell responsiveness. Cardiovasc. Res. Suppl., 2014, 103, S5.
174. Chistyakov, D.V.; Aleshin, S.E.; Astakhova, A.A.; Sergeeva, M.G.; Reiser, G. Regulation of peroxisome proliferator-activated receptors (PPAR) α and -γ of rat brain astrocytes in the course of activation by toll-like receptor agonists. J. Neurochem., 2015, doi: 10.1111/jnc.13101.
175. Deng, J.; Ma-Krupa, W.; Gewirtz, A.T.; Younge, B.R.; Goronzy, J.J.; Weyand, C.M. Toll-like receptors 4 and 5 induce distinct types of vasculitis. Circ. Res., 2009, 104, 488-495.
176. Li, X.; Melief, E.; Postupna, N.; Montine, K.S.; Keene, C.D.; Montine, T.J. Prostaglandin E2 receptor subtype 2 regulation of scavenger receptor CD36 modulates microglial Aβ42 phagocytosis. Am. J. Pathol., 2015, 185, 230-239.
177. Diebold, S.S.; Kaisho, T.; Hemmi, H.; Akira, S.; Reis e Sousa, C. Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science, 2004, 303, 1529-1531.
178. Lund, J.M.; Alexopoulou, L.; Sato, A.; Karow, M.; Adams, N.C.; Gale, N.W.; Iwasaki, A.; Flavell, R.A. Recognition of single-stranded RNA viruses by Toll-like receptor 7. Proc. Natl. Acad. Sci. USA., 2004, 101, 5598-5603.
179. Lederman, M.M. A surprising role for TLR7. Nat. Immunol., 2015, 16, 8-9.
180. Bikker, A.; Kruize, A.A.; van der Wurff-Jacobs, K.M.; Peters, R.P.; Kleinjan, M.; Redegeld, F.; de Jager, W.; Lafeber, F.P.; van Roon, J.A. Interleukin-7 and Toll-like receptor 7 induce synergistic B cell and T cell activation. PLoS One, 2014, 9, e94756.
181. Marques, J.T.; Williams, B.R.G. Activation of the mammalian immune system by siRNAs. Nat. Biotechnol., 2005, 23, 1399e405.
182. Sato, K.; Ishikawa, T.; Okumura, A.; Yamauchi, T.; Sato, S.; Ayada, M.; Matsumoto, E.; Hotta, N.; Oohashi, T.; Fukuzawa, Y. Expression of Toll-like receptors in chronic hepatitis C virus infection. J. Gastroenterol. Hepatol., 2007, 22, 1627-1632.
183. Lester, R.T.; Yao, X.D.; Ball, T.B.; McKinnon, L.R.; Kaul, R.; Wachihi, C.; Jaoko, W.; Plummer, F.A.; Rosenthal, K.L. Toll-like receptor expression and responsiveness are increased in viraemic HIV-1 infection. AIDS, 2008, 22, 685-694.
184. Komatsuda, A.; Wakui, H.; Iwamoto, K.; Ozawa, M.; Togashi, M.; Masai, R.; Maki, N.; Hatakeyama, T.; Sawada, K. Up-regulated expression of Toll-like receptors mRNAs in peripheral blood mononuclear cells from patients with systemic lupus erythematosus. Clin. Exp. Immunol., 2008, 152, 482-487.
185. Salagianni, M.; Galani, I.E.; Lundberg, A.M.; Davos, C.H.; Varela, A.; Gavriil, A.; Lyytikainen, L.P.; Lehtimaki, T.; Sigala, F.; Folkersen, L.; Gorgoulis, V.; Lenglet, S.; Montecucco, F.; Mach, F.; Hedin, U.; Hansson, G.K.; Monaco, C.; Andreakos, E. Toll-like receptor 7 protects from atherosclerosis by constraining "inflammatory" macrophage activation. Circulation, 2012, 126, 952-962.
186. Karper, J.C.; Ewing, M.M.; Habets, K.L.; de Vries, M.R.; Peters, E.A.; van Oeveren-Rietdijk, A.M.; de Boer, H.C.; Hamming, J.F.; Kuiper, J.; Kandimalla, E.R.; La Monica, N.; Jukema, J.W.; Quax, P.H. Blocking toll-like receptors 7 and 9 reduces postinterventional remodeling via reduced macrophage activation, foam cell formation, and migration. Arterioscler. Thromb. Vasc. Biol., 2012, 32, e72-80.
187. Magra, A.L.; Mertz, P.S.; Torday, J.S.; Londos, C. Role of adipose differentiation-related protein in lung surfactant production: a reassessment. J. Lipid Res., 2006, 47, 2367-2373.
188. Robenek, H.; Robenek, M.J.; Buers, I.; Lorkowski, S.; Hofnagel, O.; Troyer, D.; Severs, N.J. Lipid droplets gain PAT family proteins by interaction with specialized plasma membrane domains. J. Biol. Chem., 2005, 280, 26330-26338.
189. Robenek, H.; Robenek, M.J.; Troyer, D. PAT family proteins pervade lipid droplet cores. J. Lipid Res., 2005, 46, 1331-1338.
190. Wolins, N.E.; Quaynor, B.K.; Skinner, J.R.; Schoenfish, M.J.; Tzekov, A.; Bickel, P.E. S3-12, Adipophilin, and TIP47 package lipid in adipocytes. J. Biol. Chem., 2005, 280, 19146-19155.
191. Llorente-Cortes, V.; Royo, T.; Juan-Babot, O.; Badimon, L. Adipocyte differentiation-related protein is induced by LRP1-mediated aggregated LDL internalization in human vascular smooth muscle cells and macrophages. J. Lipid Res., 2007, 48, 2133-2140.
192. Triantafilou, K.; Orthopoulos, G.; Vakakis, E.; Ahmed, M.A.; Golenbock, D.T.; Lepper, P.M.; Triantafilou, M. Human cardiac inflammatory responses triggered by Coxsackie B viruses are mainly Toll-like receptor (TLR) 8-dependent. Cell Microbiol., 2005, 7, 1117-1126.
193. Satoh, M.; Akatsu, T.; Ishikawa, Y.; Minami, Y.; Takahashi, Y.; Nakamura, M. Association between toll-like receptor 8 expression and adverse clinical outcomes in patients with enterovirus-associated dilated cardiomyopathy. Am. Heart J., 2007, 154, 581-588.
194. Cervantes, J.L.; Dunham-Ems, S.M.; La Vake, C.J.; Petzke, M.M.; Sahay, B.; Sellati, T.J.; Radolf, J.D.; Salazar, J.C. Phagosomal signaling by Borrelia burgdorferi in human monocytes involves Toll-like receptor (TLR) 2 and TLR8 cooperativity and TLR8-mediated induction of IFN-beta. Proc. Natl. Acad. Sci. USA., 2011, 108, 3683-3688.
195. Gantier, M.P.; Irving, A.T.; Kaparakis-Liaskos, M.; Xu, D.; Evans, V.A.; Cameron, P.U.; Bourne, J.A.; Ferrero, R.L.; John, M.; Behlke, M.A.; Williams, B.R. Genetic modulation of TLR8 response following bacterial phagocytosis. Hum. Mutat., 2010, 31, 1069-1079.
196. Kariko, K.; Buckstein, M.; Ni, H.; Weissman, D. Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. Immunity, 2005, 23, 165-175.
197. Sander, L.E.; Davis, M.J.; Boekschoten, M.V.; Amsen, D.; Dascher, C.C.; Ryffel, B.; Swanson, J.A.; Muller, M.; Blander, J.M. Detection of prokaryotic mRNA signifies microbial viability and promotes immunity. Nature, 2011, 474, 385-389.
198. Lund, J.; Sato, A.; Akira, S.; Medzhitov, R.; Iwasaki, A. Toll-like receptor 9-mediated recognition of Herpes simplex virus-2 by plasmacytoid dendritic cells. Exp. Med., 2003, 198, 513-520.
199. Hemmi, H.; Takeuchi, O.; Kawai, T.; Kaisho, T.; Sato, S.; Sanjo, H.; Matsumoto, M.; Hoshino, K.; Wagner, H.; Takeda, K.; Akira, S. A Toll-like receptor recognizes bacterial DNA. Nature, 2000, 408, 740-745.
200. Liu, Y.J. IPC: professional type 1 interferon-producing cells and plasmacytoid dendritic cell precursors. Annu. Rev. Immunol., 2005, 23, 275-306.
201. Wang, J.; Lau, K.Y.; Jung, J.; Ravindran, P.; Barrat, F.J. Bruton's tyrosine kinase regulates TLR9 but not TLR7 signaling in human plasmacytoid dendritic cells. Eur. J. Immunol., 2014, 44, 1130-1136.
202. Wagner, H. The immunobiology of the TLR9 subfamily. Trends Immunol., 2004, 25, 381-386.
203. Sorrentino, R.; Morello, S.; Chen, S.; Bonavita, E.; Pinto, A. The activation of liver X receptors inhibits toll-like receptor-9-induced foam cell formation. J. Cell Physiol., 2010, 223, 158-167.
204. Bouaziz, J.D.; Calbo, S.; Maho-Vaillant, M.; Saussine, A.; Bagot, M.; Bensussan, A.; Musette, P. IL-10 produced by activated human B cells regulates CD4(+) T-cell activation in vitro. Eur. J. Immunol., 2010, 40, 2686-2691.
205. Koulis, C.; Chen, Y.C.; Hausding, C.; Ahrens, I.; Kyaw, T.S.; Tay, C.; Allen, T.; Jandeleit-Dahm, K.; Sweet, M.J.; Akira, S.; Bobik, A.; Peter, K.; Agrotis, A. Protective role for Toll-like receptor-9 in the development of atherosclerosis in apolipoprotein E-deficient mice. Arterioscler. Thromb. Vasc. Biol., 2014, 34, 516-525.
206. Ma, C.; Ouyang, Q.; Huang, Z.; Chen, X.; Lin, Y.; Hu, W.; Lin, L. Toll-like receptor 9 inactivation alleviated atherosclerotic progression and inhibited macrophage polarized to M1 phenotype in ApoE-/- Mice. Dis. Markers, 2015, doi: 10.1155/2015/909572.
207. Ivanov, S.; Dragoi, A.M.; Wang, X.; Dallacosta, C.; Louten, J.; Musco, G.; Sitia, G.; Yap, G.S.; Wan, Y.; Biron, C.A.; Bianchi, M.E.; Wang, H.; Chu, W.M. A novel role for HMGB1 in TLR9-mediated inflammatory responses to CpG-DNA. Blood, 2007, 110, 1970-1981.
208. Hirata, Y.; Kurobe, H.; Higashida, M.; Fukuda, D.; Shimabukuro, M.; Tanaka, K.; Higashikuni, Y.; Kitagawa, T.; Sata, M. HMGB1 plays a critical role in vascular inflammation and lesion formation via toll-like receptor 9. Atherosclerosis, 2013, 231, 227-233.
209. Krieg, A.M.; Yi, A.K.; Matson, S.; Waldschmidt, T.J.; Bishop, G.A.; Teasdale, R.; Koretzky, G.A.; Klinman, D.M. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature, 1995, 374, 546-549.
210. Sparwasser, T.; Koch, E.S.; Vabulas, R.M.; Heeg, K.; Lipford, G.B.; Ellwart, J.W.; Wagner, H. Bacterial DNA and immunostimulatory CpG oligonucleotides trigger maturation and activation of murine dendritic cells. Eur. J. Immunol., 1998, 28, 2045-2054.
211. Thon, J.N.; Peters, C.G.; Machlus, K.R.; Aslam, R.; Rowley, J.; Macleod, H.; Devine, M.T.; Fuchs, T.A.; Weyrich, A.S.; Semple, J.W.; Flaumenhaft, R.; Italiano J.E. Jr. T granules in human platelets function in TLR9 organization and signaling. J. Cell Biol., 2012, 198, 561-574.
212. Hasan, U.; Chaffois, C.; Gaillard, C.; Saulnier, V.; Merck, E.; Tancredi, S.; Guiet, C.; Briere, F.; Vlach, J.; Lebecque, S.; Trinchieri, G.; Bates, E.E. Human TLR10 is a functional receptor, expressed by B cells and plasmacytoid dendritic cells, which activates gene transcription through MyD88. J. Immunol., 2005, 174, 2942-2950.
213. Guan, Y.; Ranoa, D.R.; Jiang, S.; Mutha, S.K.; Li, X.; Baudry, J.; Tapping, R.I. Human TLRs 10 and 1 share common mechanisms of innate immune sensing but not signaling. J. Immunol., 2010, 184, 5094-5103.
214. Lee, S.M.; Kok, K.H.; Jaume, M.; Cheung, T.K.; Yip, T.F.; Lai, J.C.; Guan, Y.; Webster, R.G.; Jin, D.Y.; Peiris, J.S. Toll-like receptor 10 is involved in induction of innate immune responses to influenza virus infection. Proc. Natl. Acad. Sci. USA., 2014, 111, 3793-3798.
215. Suzuki, N.; Suzuki, S.; Duncan, G.S.; Millar, D.G.; Wada, T.; Mirtsos, C.; Takada, H.; Wakeham, A.; Itie, A.; Li, S.; Penninger, J.M.; Wesche, H.; Ohashi, P.S.; Mak, T.W.; Yeh, W.C. Severe impairment of interleukin-1 and Toll-like receptor signaling in mice lacking IRAK-4. Nature, 2002, 416, 750-756.
216. Zhang, F.X.; Kirschning, C.J.; Mancinelli, R.; Xu, X.P.; Jin, Y.; Faure, E.; Mantovani, A.; Rothe, M.; Muzio, M.; Arditi, M. Bacterial lipopolysaccharide activates nuclear factorkappab through interleukin-1 signaling mediators in cultured human dermal endothelial cells and mononuclear phagocytes. J. Biol. Chem., 1999, 274, 7611-7614.
217. Luu, K.; Greenhill, C.J.; Majoros, A.; Decker, T.; Jenkins, B.J.; Mansell, A. STAT1 plays a role in TLR signal transduction and inflammatory responses. Immunol. Cell Biol., 2014, 92, 761-769.
218. Yamamoto, M.; Sato, S.; Hemmi, H.; Uematsu, S.; Hoshino, K.; Kaisho, T.; Takeuchi, O.; Takeda, K.; Akira, S. TRAM is specifically involved in the Toll-like receptor 4-mediated MyD88-independent signaling pathway. Nat. Immunol., 2003, 4, 1144-1150.
219. Lee, J.; Mira-Arbibe, L.; Ulevitch, R.J. TAK1 regulates multiple protein kinase cascades activated by bacterial lipopolysaccharide. J. Leukoc. Biol., 2000, 68, 909-915.
220. Akira, S.; Takeda, K. Toll-like receptor signalling. Nat. Rev. Immunol., 2004, 4, 499-511.
221. Yamamoto, M,; Sato, S.; Hemmi, H.; Hoshino, K.; Kaisho, T.; Sanjo, H.; Takeuchi, O.; Sugiyama, M.; Okabe, M.; Takeda, K.; Akira, S. Role of adaptor TRIF in the MyD88-independent toll-like receptor signaling pathway. Science, 2003, 301, 640-643.
222. Knuefermann, P.; Sakata, Y.; Baker, J.S.; Huang, C.H.; Sekiguchi, K.; Hardarson, H.S.; Takeuchi, O.; Akira, S.; Vallejo, J.G. Toll-like receptor 2 mediates Staphylococcus aureus-induced myocardial dysfunction and cytokine production in the heart. Circulation, 2004, 110, 3693-3698.
223. Shishido, T.; Nozaki, N.; Takahashi, H.; Arimoto, T.; Niizeki, T.; Koyama, Y.; Abe, J.; Takeishi, Y.; Kubota, I. Central role of endogenous Toll-like receptor-2 activation in regulating inflammation, reactive oxygen species production, and subsequent neointimal formation after vascular injury. Biochem. Biophys. Res. Commun., 2006, 345, 1446-1453.
224. Favre, J.; Musette, P.; Douin-Echinard, V.; Laude, K.; Henry, J.P.; Arnal, J.F.; Thuillez, C.; Richard, V. Toll-like receptors 2-deficient mice are protected against postischemic coronary endothelial dysfunction. Arterioscler. Thromb. Vasc. Biol., 2007, 27, 1064-1071.
225. Arslan, F.; Smeets, M.B.; O'Neill, L.A.; Keogh, B.; McGuirk, P.; Timmers, L.; Terstee, C.; Hoefer, I.E.; Doevendans, P.A.; Pasterkamp, G.; de Kleijn, D.P. Myocardial ischemia/reperfusion injury is mediated by leukocytic toll-like receptor-2 and reduced by systemic administration of a novel anti-toll-like receptor-2 antibody. Circulation, 2010, 121, 80-90.
226. Ha, T.; Li, Y.; Hua, F.; Ma, J.; Gao, X.; Kelley, J.; Zhao, A.; Haddad, G.E.; Williams, D.L.; William Browder, I.; Kao, R.; Li, C. Reduced cardiac hypertrophy in toll-like receptor 4-deficient mice following pressure overload. Cardiovasc. Res., 2005, 68, 224-234.
227. Oyama, J.; Blais, C. Jr.; Liu, X.; Pu, M.; Kobzik, L.; Kelly, R.A.; Bourcier, T. Reduced myocardial ischemiareperfusion injury in toll-like receptor 4-deficient mice. Circulation, 2004, 109, 784-789.
228. Holloway, J.W.; Yang, I.A.; Ye, S. Variation in the toll-like receptor 4 gene and susceptibility to myocardial infarction. Pharmacogenet. Genomics, 2005, 15, 15-21.
229. Lin, Y.C.; Chang, Y.M.; Yu, J.M.; Yen, J.H.; Chang, J.G.; Hu, C.J. Toll-like receptor 4 gene C119A but not Asp299Gly polymorphism is associated with ischemic stroke among ethnic Chinese in Taiwan. Atherosclerosis, 2005, 180, 305-309.
230. Grote, K.; Sonnenschein, K.; Kapopara, P.R.; Hillmer, A.; Grothusen, C.; Salguero, G.; Kotlarz, D.; Schuett, H.; Bavendiek, U.; Schieffer, B. Toll-like receptor 2/6 agonist macrophage-activating lipopeptide-2 promotes reendothelialization and inhibits neointima formation after vascular injury. Arterioscler. Thromb. Vasc. Biol., 2013, 33, 2097-2104.
231. Erridge, C.; Burdess, A.; Jackson, A.J.; Murray, C.; Riggio, M.; Lappin, D.; Milligan, S.; Spickett, C.M.; Webb, D.J. Vascular cell responsiveness to Toll-like receptor ligands in carotid atheroma. Eur. J. Clin. Invest., 2008, 38, 713-720.
232. Nicolaou, G.; Goodall, A.H.; Erridge, C. Diverse bacteria promote macrophage foam cell formation via Toll-like receptor-dependent lipid body biosynthesis. J. Atheroscler. Thromb., 2012, 19, 137-148.
233. Park, J.S.; Gamboni-Robertson, F.; He, Q.; Svetkauskaite, D.; Kim, J.Y.; Strassheim, D.; Sohn, J.W.; Yamada, S.; Maruyama, I.; Banerjee, A.; Ishizaka, A.; Abraham, E. High mobility group box 1 protein interacts with multiple Tolllike receptors. Am. J. Physiol. Cell Physiol., 2006, 290, C917-924.
234. Vogl, T.; Tenbrock, K.; Ludwig, S.; Leukert, N.; Ehrhardt, C.; van Zoelen, M.A.; Nacken, W.; Foell, D.; van der Poll, T.; Sorg, C.; Roth, J. Mrp8 and Mrp14 are endogenous activators of Toll-like receptor 4, promoting lethal, endotoxininduced shock. Nat. Med., 2007, 13, 1042-1049.
235. Sandri, S.; Rodriguez, D.; Gomes, E.; Monteiro, H.P.; Russo, M.; Campa, A. Is serum amyloid A an endogenous TLR4 agonist? J. Leukoc. Biol., 2008, 83, 1174-1180.
236. Babelova, A.; Moreth, K.; Tsalastra-Greul, W.; Zeng-Brouwers, J.; Eickelberg, O.; Young, M.F.; Bruckner, P.; Pfeilschifter, J.; Schaefer, R.M.; Grone, H.J.; Schaefer, L. Biglycan, a danger signal that activates the NLRP3 inflammasome via Toll-like and P2X receptors. J. Biol. Chem., 2009, 284, 24035-24048.
237. Schaefer, L.; Babelova, A.; Kiss, E.; Hausser, H.J.; Baliova, M.; Krzyzankova, M.; Marsche, G.; Young, M.F.; Mihalik, D.; Gotte, M.; Malle, E.; Schaefer, R.M.; Grone, H.J. The matrix component biglycan is proinflammatory and signals through Toll-like receptors 4 and 2 in macrophages. J. Clin. Invest., 2005, 115, 2223-2233.
238. Duewell, P.; Kono, H.; Rayner, K.J.; Sirois, C.M.; Vladimer, G.; Bauernfeind, F.G.; Abela, G.S.; Franchi, L.; Nunez, G.; Schnurr, M.; Espevik, T.; Lien, E.; Fitzgerald, K.A.; Rock, K.L.; Moore, K.J.; Wright, S.D.; Hornung, V.; Latz, E. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature, 2010, 464, 1357-1361.
239. Burckstummer, T.; Baumann, C.; Bluml, S.; Dixit, E.; Durnberger, G.; Jahn, H.; Planyavsky, M.; Bilban, M.; Colinge, J.; Bennett, K.L.; Superti-Furga, G. An orthogonal proteomicgenomic screen identifies AIM2 as a cytoplasmic DNA sensor for the inflammasome. Nat. Immunol., 2009, 10, 266-272.
240. Fernandes-Alnemri, T.; Yu, J.W.; Datta, P.; Wu, J.; Alnemri, E.S. AIM2 activates the inflammasome and cell death in response to cytoplasmic DNA. Nature, 2009, 458, 509-513.
241. Hornung, V.; Ablasser, A.; Charrel-Dennis, M.; Bauernfeind, F.; Horvath, G.; Caffrey, D.R.; Latz, E.; Fitzgerald, K.A. AIM2 recognizes cytosolic dsDNA and forms a caspase-1-activating inflammasome with ASC. Nature, 2009, 458, 514-518.
242. Zhang, Q.; Raoof, M.; Chen, Y.; Sumi, Y.; Sursal, T.; Junger, W.; Brohi, K.; Itagaki, K.; Hauser, C.J. Circulating mitochondrial DAMPs cause inflammatory responses to injury. Nature, 2010, 464, 104-107.
243. Johnson, G.B.; Brunn, G.J.; Kodaira, Y.; Platt, J.L. Receptor-mediated monitoring of tissue well-being via detection of soluble heparan sulfate by Toll-like receptor 4. J. Immunol., 2002, 168, 5233-5239.
244. Yu, M.; Wang, H.; Ding, A.; Golenbock, D.T.; Latz, E.; Czura, C.J.; Fenton, M.J.; Tracey, K.J.; Yang, H. HMGB1 signals through Toll-like receptor (TLR) 4 and TLR2. Shock, 2006, 26, 174-179.
245. Tian, J.; Avalos, A.M.; Mao, S.Y.; Chen, B.; Senthil, K.; Wu, H.; Parroche, P.; Drabic, S.; Golenbock, D.; Sirois, C.; Hua, J.; An, L.L.; Audoly, L.; La Rosa, G.; Bierhaus, A.; Naworth, P.; Marshak-Rothstein, A.; Crow, M.K.; Fitzgerald, K.A.; Latz, E.; Kiener, P.A.; Coyle, A.J. Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE. Nat. Immunol., 2007, 8, 487-496.
246. Quintana, F.J.; Cohen, I.R. Heat shock proteins as endogenous adjuvants in sterile and septic inflammation. J. Immunol., 2005, 175, 2777-2782.
247. Vabulas, R.M.; Ahmad-Nejad, P.; da Costa, C.; Miethke, T.; Kirschning, C.J.; Hacker, H.; Wagner, H. Endocytosed HSP60s use Toll-like receptor 2 (TLR2) and TLR4 to activate the Toll/interleukin-1 receptor signaling pathway in innate immune cells. J. Biol. Chem., 2001, 276, 31332-31339.
248. Jiang, D.; Liang, J.; Fan, J.; Yu, S.; Chen, S.; Luo, Y.; Prestwich, G.D.; Mascarenhas, M.M.; Garg, H.G.; Quinn, D.A.; Homer, R.J.; Goldstein, D.R.; Bucala, R.; Lee, P.J.; Medzhitov, R.; Noble, P.W. Regulation of lung injury and repair by Toll-like receptors and hyaluronan. Nat. Med., 2005, 11, 1173-1179.
249. Scheibner, K.A.; Lutz, M.A.; Boodoo, S.; Fenton, M.J.; Powell, J.D.; Horton, M.R. Hyaluronan fragments act as an endogenous danger signal by engaging TLR2. J. Immunol., 2006, 177, 1272-1281.
250. Taylor, K.R.; Yamasaki, K.; Radek, K.A.; Di Nardo, A.; Goodarzi, H.; Golenbock, D.; Beutler, B.; Gallo, R.L. Recognition of hyaluronan released in sterile injury involves a unique receptor complex dependent on Toll-like receptor 4, CD44, and MD-2. J. Biol. Chem., 2007, 282, 18265-18275.
251. Kariko, K.; Ni, H.; Capodici, J.; Lamphier, M.; Weissman, D. mRNA is an endogenous ligand for Toll-like receptor 3. J. Biol. Chem., 2004, 279, 12542-12550.
252. Kim, S.; Takahashi, H.; Lin, W.W.; Descargues, P.; Grivennikov, S.; Kim, Y.; Luo, J.L.; Karin, M. Carcinomaproduced factors activate myeloid cells through TLR2 to stimulate metastasis. Nature, 2009, 457, 102-106.
253. Subramanian, M.; Thorp, E.; Hansson, G.K.; Tabas, I. Tregmediated suppression of atherosclerosis requires MYD88 signaling in DCs. J. Clin. Invest., 2013, 123, 179-188.
254. Thompson, J.C.; Tang, T.; Wilson, P.G.; Yoder, M.H.; Tannock, L.R. Increased atherosclerosis in mice with increased vascular biglycan content. Atherosclerosis, 2014, 235, 71-75.
255. Appiah, D.; Schreiner, P.J.; MacLehose, R.F.; Folsom, A.R. Association of plasma γ' fibrinogen with incident cardiovascular disease: the atherosclerosis risk in communities (ARIC) study. Arterioscler. Thromb. Vasc. Biol., 2015, 35(12), 2700-2706.
256. Rao, G.; Ding, H.G.; Huang, W.; Le, D.; Maxhimer, J.B.; Oosterhof, A.; van Kuppevelt, T.; Lum, H.; Lewis, E.J.; Reddy, V.; Prinz, R.A.; Xu, X. Reactive oxygen species mediate high glucose-induced heparanase-1 production and heparan sulphate proteoglycan degradation in human and rat endothelial cells: a potential role in the pathogenesis of atherosclerosis. Diabetologia, 2011, 54, 1527-1538.
257. Venu, P.V.K.; Uboldi, P.; Dhyani, A.; Patrini, A.; Baetta, R.; Ferri, N.; Corsini, A.; Muro, A.F.; Catapano, A.L.; Norata, G.D. Fibronectin extra domain A stabilises atherosclerotic plaques in apolipoprotein E and in LDL-receptordeficient mice. Thromb. Haemost., 2015, 114, 186-197.
258. Xiao, Q.; Mandal, K.; Schett, G.; Mayr, M.; Wick, G.; Oberhollenzer, F.; Willeit, J.; Kiechl, S.; Xu, Q. Association of serum-soluble heat shock protein 60 with carotid atherosclerosis: clinical significance determined in a followup study. Stroke, 2005, 36, 2571-2576.
259. Henriksen, P.A.; Sallenave, J.M. Human neutrophil elastase: mediator and therapeutic target in atherosclerosis. Int. J. Biochem. Cell Biol., 2008, 40, 1095-1100.
260. Ionita, M.G.; Vink, A.; Dijke, I.E.; Laman, J.D.; Peeters, W.; van der Kraak, P.H.; Moll, F.L.; de Vries, J.P.; Pasterkamp, G.; de Kleijn, D.P. High levels of myeloid-related protein 14 in human atherosclerotic plaques correlate with the characteristics of rupture-prone lesions. Arterioscler. Thromb. Vasc. Biol., 2009, 29, 1220-1227.
261. Oesterle, A.; Bowman, M.A. S100A12 and the S100/calgranulins: emerging biomarkers for atherosclerosis and possibly therapeutic targets. Arterioscler. Thromb. Vasc. Biol., 2015, ATVBAHA.115.302072. [Epub ahead of print]
262. Chiba, T.; Chang, M.Y.; Wang, S.; Wight, T.N.; McMillen, T.S.; Oram, J.F.; Vaisar, T.; Heinecke, J.W.; De Beer, F.C.; De Beer, M.C.; Chait, A. Serum amyloid A facilitates the binding of HDL from mice injected with lipopolysaccharide to vascular proteoglycans. Arterioscler. Thromb. Vasc. Biol., 2011, 31, 1326-1332.
263. Barascuk, N.; Genovese, F.; Larsen, L.; Byrjalsen, I.; Zheng, Q.; Sun, S.; Hosbond, S.; Poulsen, T.S.; Diederichsen, A.; Jensen, J.M.; Mickley, H.; Register, T.C.; Rasmussen, L.M.; Leeming, D.J.; Christiansen, C.; Karsdal, M.A. A MMP derived versican neo-epitope is elevated in plasma from patients with atherosclerotic heart disease. Int. J. Clin. Exp. Med., 2013, 6, 174-184.
264. Jimenez-Dalmaroni, M.J.; Gerswhin, M.E.; Adamopoulos, I.E. The critical role of toll-like receptors - From microbial recognition to autoimmunity: A comprehensive review. Autoimmun. Rev., 2016, 15(1), 1-8.
265. Jimenez-Dalmaroni, M.J.; Radcliffe, C.M.; Harvey, D.J.; Wormald, M.R.; Verdino, P.; Ainge, G.D.; Larsen, D.S.; Painter, G.F.; Ulevitch, R.; Beutler, B.; Rudd, P.M.; Dwek, R.A.; Wilson, I.A. Soluble human TLR2 ectodomain binds diacylglycerol from microbial lipopeptides and glycolipids. Innate Immun., 2015, 21, 175-193.
266. Bartfai, T.; Behrens, M.M.; Gaidarova, S.; Pemberton, J.; Shivanyuk, A.; Rebek, J. Jr. A low molecular weight mimic of the Toll/IL-1 receptor/resistance domain inhibits IL-1 receptor-mediated responses. Proc. Natl. Acad. Sci. USA., 2003, 100, 7971-7976.